This research project is testing a new treatment for Macular oedema. The new treatment is called KIO-104.

Macular oedema is a complication of many eye diseases. Fluid builds up in the retina, at the back of the eye, causing swelling and thickening of the retina. This can lead to symptoms including but not limited to blurry vision and reduced contrast or colour sensitivity in your vision.

The fluid build up can be caused by many different diseases. Depending on the cause, treatment options include corticosteroids, anti-vascular endothelial growth factor (VEGF) therapies, non-steroidal anti-inflammatory drugs (NSAIDs), diuretics, and drugs which affect your immune system.

While these treatments are effective for a lot of people, they can have serious side effects. Many people are also treatment resistant, meaning that they don’t respond to the drugs.

KIO-104 is a different type of drug that aims to blocks some of the pathways that cause inflammation (swelling). There are already some approved medications that act on the same pathway as KIO-104, which are used to treat inflammation associated with arthritis and multiple sclerosis, however, there are no approved drugs like this for the eye.

This study will test if KIO-104 is safe and effective in reducing the swelling and improving vision when it is given as an injection into the affected eye. Those with macular oedema secondary to non-infectious uveitis, retinal vein occlusion, diabetic retinopathy or cataract surgery may be considered for this study.

The study will run for approximately 4 months. For further information about this study please contact the Clinical Trials Research Centre on (03) 9929 8076 or email info@ceruleaclinicaltrials.org.au